Shire’s focus on rare diseases paid off with growth in the first quarter driven by product sales in haematology and immunology.
Showing 25 of 2096
Under the terms of the deal, the FTSE 100-listed firm will receive regular quarterly orders for myLotus meters from SinoPharm, with 50% upfront payment and 50% paid on delivery
The drugmaker reported a 2% decline in first quarter adjusted earnings as a stronger pound and pricing pressure provided a drag
The new offer from Takeda values Shire at around £46bn, or £49 per share, up from its previous bid of £43bn
The grant comes hot on the heels of a patent grant for the treatment in the US on 20 March
Has the Japanese drugs giant sweetened further the cash element of its £43bn offer?
Chairman Iain Ross will step back into a non-executive role following the appointment
Steve Harris, Circassia’s chief executive, said he expected to see strong revenue growth in 2018
AZ’s Imfinzi was paired with tremelimumab, an immune checkpoint blocker, to treat patients with non-small cell lung cancer
2018 is shaping up to be a crucial year for the company's drug pipeline
The pair said the debate around the company's flagship drug is far more 'nuanced' than the top-line data might suggest, which explains why potential licensing partners are keen to continue talking to management
Next week we'll see the colour of Takeda's money. Will rival bidders emerge from the woodwork?
At 4:20pm, thousands around the world will participate in a synchronized smoke-off.
Takeda faces a bidding war for Shire following a report that Allergan is in talks to buy the London-listed firm
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
In a note to clients, analysts for the broker said the biotech firm had indicated a more coherent strategy that reflected value despite recent weak share performance
The company is developing VAL101 in collaboration with academic and commercial partners in Finland, Germany and Denmark
In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline
“We need to see more data,” said Northland Capital's Vadim Alexandre. “There is a major unmet medical"
Trigen Pharma will distribute and commercialise OptiBiotix’s cholesterol- and blood pressure-reducing CholBiome products in Pakistan
Gupte also sees the news as positive for Cigna's deal to buy Express Scripts
The company revealed there had been "expressions of interest" in its lupus programme which it will explore
The cream has been formulated to contain SkinBioTherapeutics' proprietary technology, SkinBiotix; tests have proved the cream formulation retains the same beneficial properties as the original technology
Takeda is reportedly preparing to launch a bid for Shire before the April 25 deadline, but Shire’s oncology unit was one of the key reasons it wanted the takeover in the first place